I. MODIFIED AGREEMENTS | |||
Company* (Country; Symbol) |
Company* (Country; Symbol) |
Change from original agreement |
Terms/Details (Date) |
| |||
Genencor International Inc. (GCOR) |
Ciphergen Biosystem Inc. (CIPH) |
Expansion of license agreement covering production and marketing of products based on Genencor's Hydrophobic Charge Induction chromatography technology |
Ciphergen uses the technology in the production of MEP HyperCel sorbent; Ciphergen gets the right to use and distribute products based on the technology (1/21) |
|
|||
Genentech Inc. (NYSE:DNA) and Novartis Pharma AG (Switzerland) |
Tanox Inc. (TNOX) |
Companies finalized terms settling all litigation related to three-way deal on developing anti-IgE antibodies, including Xolair and TNX-901 |
Genentech and Novartis each will reimburse Tanox $3.3 million for TNX-901 development costs; Tanox will relinquish any rights to manufacture Xolair, and will receive payments tied to the quantity of Xolair produced; and Tanox will get accelerated forgiveness of a manufacturing loan; royalty and profit-sharing arrangements remain the same (2/26) |
|
|||
MorphoSys AG (Germany; FSE:MOR) |
GPC Biotech AG* (Germany) |
GPC extended its exclusive license for HuCAL antibodies directed against an MHC Class II target molecule |
MorphoSys received an undisclosed payment (1/28) |
|
|||
Seattle Genetics Inc. (SGEN) |
Protein Design Labs Inc. (PDLI) |
Expanded antibody-drug conjugate deal under which SGI will provide additional R&D support for product development |
SGI will get increased fees, milestones and royalties under the modified deal; PDL has rights to exclusive licenses to the technology for use with antibodies against targets it selects (1/12) |
|
|||
II. TERMINATED AGREEMENTS | |||
|
|||
Genome Therapeutics Corp. (GENE) |
Amgen Inc. (AMGN) |
Companies ended January 2003 collaboration focused on discovering and developing therapeutics for bone diseases |
Genome Therapeutics retains certain intel- lectual property and licensing rights related to a gene discovered during the collaboration (1/9) |
|
|||
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange. |